Akeso Inc.
http://www.akesobio.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akeso Inc.
ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs
The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.
Finance Watch: Follow-Ons Bring In Big Post-Data Cash For Nuvalent And Others
Public Company Edition: Follow-on public offerings brought in $500m for Nuvalent, $235m for Summit and $225m each for Centessa and Viridian after recent readouts. Also, Kairos raised $6.2m in this year’s 19th IPO, Bayer sold €750m ($834m) in bonds and an Ionis FOPO grossed $500.3m.
ESMO 24: Summit/Akeso Broaden Base Of Solid Tumor Indications For Anti-PD-1xVEGF Bispecific
Phase II data at the ESMO meeting showed promising efficacy for the drug beyond NSCLC, particularly in certain indications of colorectal and head-and-neck cancers.
Aiming For Keytruda’s Crown, Summit Raises Extra Funds To Fuel Ivonescimab Ambitions
The US company believes it can not only beat Keytruda at its own game, but also achieve success where Merck & Co's blockbuster and other immunotherapies have failed.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Akesobio
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice